A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.

Miller DS, Brady MF, Barrett RJ

American journal of clinical oncology1 Apr 1992Cited by 21 (Europe PMC)

PMID1553899DOI10.1097/00000421-199204000-00006PepBankPUB-01553899

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with advanced or recurrent ovarian carcinoma, leuprolide produced one partial response among 25 patients (4%).
In plain wordsIn patients with advanced or recurrent ovarian cancer, one of 25 patients had a partial response to leuprolide.
Peptide
Leuprolide
Outcome
Not applicablePartial response
Study
n = 25
Outcome group
Tumor response · Cancer
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Partial responses
1 patients
leuprolide
Response rate
4%
leuprolide
Upper 95% confidence bound
17.6%
response rate
Source sentences
Summary
One partial response (4%) was observed among the 25 patients. The upper 95% confidence bound of the response rate is 17.6%.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389901
02HumanNon-randomized trialEfficacy outcome
In patients with advanced or recurrent ovarian carcinoma, 15 patients (60%) had stable disease for at least 8 weeks with leuprolide.
In plain wordsIn patients with advanced or recurrent ovarian cancer, 15 patients had stable disease for at least 8 weeks with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableStable disease
Study
n = 25
Outcome group
Tumor response · Cancer
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Stable disease
15 patients
at least 8 weeks
Stable disease
60%
at least 8 weeks
Source sentences
Summary
Fifteen patients (60%) exhibited stable disease for at least 8 weeks, and 9 patients (36%) developed progressive cancer while receiving treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389902
03HumanNon-randomized trialEfficacy outcome
In patients with advanced or recurrent ovarian carcinoma, 9 patients (36%) developed progressive cancer during leuprolide treatment.
In plain wordsIn patients with advanced or recurrent ovarian cancer, nine patients developed progressive cancer during leuprolide treatment.
Peptide
Leuprolide
Outcome
Not applicableProgressive cancer
Study
n = 25
Outcome group
Tumor response · Cancer
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Progressive cancer
9 patients
leuprolide
Progressive cancer
36%
leuprolide
Source sentences
Summary
Fifteen patients (60%) exhibited stable disease for at least 8 weeks, and 9 patients (36%) developed progressive cancer while receiving treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389903
04HumanNon-randomized trialSafety outcome
In patients with advanced or recurrent ovarian carcinoma, no patient experienced life-threatening toxicity with leuprolide.
In plain wordsIn patients with advanced or recurrent ovarian cancer, no patient had life-threatening toxicity with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableLife-threatening toxicity
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
The regimen was well tolerated with no patient experiencing life-threatening toxicity.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389904
05HumanNon-randomized trialSafety outcome
In patients with ovarian carcinoma, mild leukopenia occurred in 2 patients (8%) receiving leuprolide.
In plain wordsIn patients with ovarian cancer, two patients had mild leukopenia with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableLeukopenia
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Leukopenia
2 patients
mild
Leukopenia
8%
mild
Source sentences
Summary
Mild toxicities included leukopenia in 2 patients (8%), thrombocytopenia in 2 patients (8%), gastrointestinal toxicity in 5 patients (20%), anemia in 4 patients (16%), hot flashes in 1 patient (4%), and facial swelling in 1 patient (4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389905
06HumanNon-randomized trialSafety outcome
In patients with ovarian carcinoma, mild thrombocytopenia occurred in 2 patients (8%) receiving leuprolide.
In plain wordsIn patients with ovarian cancer, two patients had mild thrombocytopenia with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableThrombocytopenia
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Thrombocytopenia
2 patients
mild
Thrombocytopenia
8%
mild
Source sentences
Summary
Mild toxicities included leukopenia in 2 patients (8%), thrombocytopenia in 2 patients (8%), gastrointestinal toxicity in 5 patients (20%), anemia in 4 patients (16%), hot flashes in 1 patient (4%), and facial swelling in 1 patient (4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389906
07HumanNon-randomized trialSafety outcome
In patients with ovarian carcinoma, mild gastrointestinal toxicity occurred in 5 patients (20%) receiving leuprolide.
In plain wordsIn patients with ovarian cancer, five patients had mild gastrointestinal toxicity with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableGastrointestinal toxicity
Study
n = 25
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Gastrointestinal toxicity
5 patients
mild
Gastrointestinal toxicity
20%
mild
Source sentences
Summary
Mild toxicities included leukopenia in 2 patients (8%), thrombocytopenia in 2 patients (8%), gastrointestinal toxicity in 5 patients (20%), anemia in 4 patients (16%), hot flashes in 1 patient (4%), and facial swelling in 1 patient (4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389907
08HumanNon-randomized trialSafety outcome
In patients with ovarian carcinoma, mild anemia occurred in 4 patients (16%) receiving leuprolide.
In plain wordsIn patients with ovarian cancer, four patients had mild anemia with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableAnemia
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Anemia
4 patients
mild
Anemia
16%
mild
Source sentences
Summary
Mild toxicities included leukopenia in 2 patients (8%), thrombocytopenia in 2 patients (8%), gastrointestinal toxicity in 5 patients (20%), anemia in 4 patients (16%), hot flashes in 1 patient (4%), and facial swelling in 1 patient (4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389908
09HumanNon-randomized trialSafety outcome
In patients with ovarian carcinoma, mild hot flashes occurred in 1 patient (4%) receiving leuprolide.
In plain wordsIn patients with ovarian cancer, one patient had mild hot flashes with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableHot flashes
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Hot flashes
1 patient
mild
Hot flashes
4%
mild
Source sentences
Summary
Mild toxicities included leukopenia in 2 patients (8%), thrombocytopenia in 2 patients (8%), gastrointestinal toxicity in 5 patients (20%), anemia in 4 patients (16%), hot flashes in 1 patient (4%), and facial swelling in 1 patient (4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389909
10HumanNon-randomized trialSafety outcome
In patients with ovarian carcinoma, mild facial swelling occurred in 1 patient (4%) receiving leuprolide.
In plain wordsIn patients with ovarian cancer, one patient had mild facial swelling with leuprolide.
Peptide
Leuprolide
Outcome
Not applicableFacial swelling
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
1 mg daily · subcutaneousAs given in this study (human).
Measurements
Facial swelling
1 patient
mild
Facial swelling
4%
mild
Source sentences
Summary
Mild toxicities included leukopenia in 2 patients (8%), thrombocytopenia in 2 patients (8%), gastrointestinal toxicity in 5 patients (20%), anemia in 4 patients (16%), hot flashes in 1 patient (4%), and facial swelling in 1 patient (4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-five evaluable patients with advanced or recurrent epithelial ovarian carcinoma that was no longer controllable with surgery, radiation therapy, and/or chemotherapy were treated with leuprolide acetate, a gonadotropin-releasing hormone agonist, 1 mg subcutaneously daily.
Report a problemFND-0155389910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.